JULIA KIMBROUGH: Open Payments
NPI 1619417581 · ARNOLD, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$809 in 35 payments from 14 companies in 2025. Trend: 2023 $819 · 2024 $686 · 2025 $809
Food & beverage: $809
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $233 |
| Boston Scientific Corporation | 3 | $118 |
| PFIZER INC. | 4 | $80 |
| ABBVIE INC. | 3 | $69 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $51 |
| AstraZeneca Pharmaceuticals LP | 2 | $48 |
| Astellas Pharma US Inc | 2 | $41 |
| Abbott Laboratories | 2 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $25 |
| TMS NeuroHealth Centers Inc. | 1 | $23 |
Products named: Ozempic, Wegovy, FARAPULSE, VRAYLAR, Rybelsus, XIFAXAN, AIRSUPRA, WaveWriter Alpha Prime 16.
Industry payments across MD — which companies pay providers there.
